Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Nutriband Signs LOI with Qvanta for Abuse-Deterrent Pharma Technology
Nutriband Inc., a developer of transdermal pharmaceutical products including abuse-deterrent technologies, announced the signing of a non-binding Letter of Intent with the Qvanta Group of Companies.
Cosan Secures Growth Funding to Expand AI Virtual Care
Cosan, a connected chronic care management company helping providers extend care beyond the clinic, announced a $15 million strategic growth equity investment led by Ziegler Link-age Funds and The Specialty Alliance, the nation’s leading physician-led Healthcare Partnership Organization and a long-standing Cosan partner.
Orum Therapeutics Raises $100 Million to Advance Degrader ADCs
Orum Therapeutics, a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), announced that it secured 145 billion KRW in convertible preferred stock investments. This round is led by returning investor KB Investment and includes other existing investors, IMM Investment, Woori Venture Partners and Stassets Investment. New investors include Weiss Asset Management, a Boston-based global investment firm, and Korea Investment Partners, a major institutional venture investor with a strong track record in biotech investment. Additional new investors in this round are DSC Investment, Company K Partners, AON Investment, and DAYLI Partners.
Pulse Biosciences Gets FDA IDE for nPulse AFib Ablation Study
Pulse Biosciences, Inc. , a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation energy, announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company’s Investigational Device Exemption (IDE), allowing Pulse Biosciences to proceed with the initiation of its nPulse Cardiac Catheter Ablation System Study for the treatment of paroxysmal atrial fibrillation.
PROSTOX Ultra Test Cuts Costs and Boosts Quality of Life in Prostate Cancer
MiraDx, a molecular diagnostics company specializing in germline genetic testing to personalize cancer treatment, announced that a new study published in the Journal of Health Economics and Outcomes Research shows the PROSTOX ultra test provides meaningful long-term economic and quality-of-life benefits for men with localized prostate cancer undergoing stereotactic body radiation therapy.
To share your insights, please write to us at sudipto@intentamplify.com
